Treatment of Hepatitis C in Special Conditions: Liver Cirrhosis.
10.3904/kjm.2015.88.6.643
- Author:
Geum Youn GWAK
1
Author Information
1. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. gy.gwak@samsung.com
- Publication Type:Review
- Keywords:
Hepatitis C;
Cirrhosis;
SVR;
Antiviral therapy
- MeSH:
Carcinoma, Hepatocellular;
Fibrosis;
Hepatitis C*;
Humans;
Incidence;
Liver;
Liver Cirrhosis*;
Mortality;
Ribavirin;
Standard of Care
- From:Korean Journal of Medicine
2015;88(6):643-646
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Acquiring a sustained virological response (SVR) in patients with cirrhosis or advanced hepatic fibrosis reduces liver disease-related mortality and the incidence of hepatocellular carcinoma. However, the SVR rate of the current standard of care, which is combination therapy with peg-interferon-alpha and ribavirin, is significantly lower, and treatment-related complications occur more frequently in patients with cirrhosis. Thus, antiviral treatment should be individualized in this population. This review highlights the issues associated with anti-hepatitis C virus treatment in patients with compensated and decompensated cirrhosis.
